Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 –– Conference call today at ...

Interparfums, Inc. Reports 2026 First Quarter Results

Q1 2026 Net Sales of $345 Million and Diluted EPS of $1.35 Per Share; Reaffirms Full Year 2026 Guidance; Quarterly Cash Dividend to be Paid on ...